VOR
USDVor Biopharma Inc. Common Stock
Preço em tempo real
Gráfico de preços
Métricas-chave
Métricas de mercado
Abertura
$21.960
Máximo
$22.000
Mínimo
$19.620
Volume
0.22M
Fundamentos da empresa
Capitalização de mercado
140.9M
Setor
Biotecnologia
País
United States
Estatísticas de negociação
Volume médio
0.36M
Bolsa de valores
NMS
Moeda
USD
Faixa de 52 semanas
Notícias relacionadas
Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer
BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Jeremy Sokolove, M.D., as
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on October 15, 2025, the Compensation
HC Wainwright & Co. Maintains Buy on Vor Biopharma, Raises Price Target to $52
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Vor Biopharma with a Buy and raises the price target from $3 to $52.
Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data
Telitacicept delivered consistent quality-of-life improvement across both treatment and placebo crossover arms 100% of patients on telitacicept for 48 weeks achieved ≥2-point Myasthenia Gravis Activities of Daily Living
Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren's Disease
CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it will host a live webcast to
Baird Upgrades Vor Biopharma to Outperform, Raises Price Target to $64
Baird analyst Jack Allen upgrades Vor Biopharma from Neutral to Outperform and raises the price target from $20 to $64.
Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren's Disease at ACR 2025
Telitacicept met primary and all secondary endpoints, demonstrating clinically meaningful improvements in disease activity versus placebo ~71.8% of patients receiving telitacicept 160mg achieved ≥3-point ESSDAI (EULAR
Ações relacionadas
BBSI
Barrett Business Services Inc.
UZF
United States Cellular Corporation 5.500% Senior Notes due 2070
POST
Post Holdings Inc.
JNJ
Johnson & Johnson
EFR
Eaton Vance Senior Floating-Rate Fund Common Shares of Beneficial Interest
Mantenha-se atualizado
Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.